Emily Menendez

GU Oncology Now

Advanced penile squamous cell carcinoma is a rare disease with a 21% 2-year overall survival (OS) rate.The single-center, nonrandomized, phase 2 PERICLES study assessed the activity of atezolizumab, an anti-PD-L1, with and without radiotherapy (RT) <a href="https://ascopubs.org/doi/abs/10.1200/JCO.22.02894" target="_blank" rel="noopener">to determine which approach is more effective in patients with advanced penile cancer.</a>The study&rsquo;s primary end point was 1-year progression-free survival (PFS) for the full cohort, which was reached if the actual 1-year PFS was at least 35%. Secondary end points included OS, objective response rate (ORR), and tolerability.A total of 31 patients with advanced penile cancer were included in the study. Each patient received atezolizumab 1200 mg once every 3 weeks, and 20 patients received additional irradiation. The median follow-up was 29.1 months.Grade 3 and 4 adverse events occurred in 3 (9.4%) patients in the atezolizumab monotherapy arm and 13 (65%) patients in the RT arm. The primary end point was not met, as the one-year PFS rate was 12.5% (95% CI, 5.5-18.7). Median OS was 11.3 months (95% CI, 5.5-18.7). In the objective response-evaluable population (n=30; 93.8%), the ORR was 16.7% (95% CI, 6-35), including 2 (6.7%) complete responders and 3 (10%) partial responders.Improved PFS was noted in patients with high-risk human papillomavirus-positive tumors (P=.003) and in patients with high infiltration of intratumoral CD3+CD8+ T cells (P=.037).While the study&rsquo;s primary end point was not met, antitumor activity from atezolizumab was seen in a subset of patients.

Atezolizumab With or Without Radiotherapy for Advanced Penile Cancer

Testicular, Penile, and Rare Malignancies

The PERICLES study assessed atezolizumab with and without radiotherapy to determine which approach is more effective for advanced penile cancer.

Atezolizumab and Radiotherapy for Advanced Penile Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe